Poseida Therapeutics (PSTX): $9.31
Market Cap: $907.40 M
Deal Size: $1.5 B
Switzerland-based Roche Holdings has agreed to acquire U.S.-based Poseida Therapeutics in a deal with an equity value of $1.5 billion. This deal will help Roche strengthen its pipeline of immune cell therapies for blood cancers. Roche will pay $9.00 per share in cash for all of Poseida’s outstanding shares, a 214.69% premium over its last closing price.
In addition, the deal includes a contingent value right (CVR), which could give Poseida shareholders up to $4.00 per share in cash if certain milestones are met. These milestones are related to Poseida’s Allo CAR T-cell therapies, such as starting key clinical trials, gaining regulatory approval, and making the first commercial sale.